Dr Reddy’s second-quarter results show a sharp profit decline, with multiple outlets reporting net profit falling by about a third. The drop is attributed primarily to weaker North America performance and lower revenues tied to lenalidomide (Revlimid), alongside a sizable provision related to semaglutide ingredients.
Outlets also flag that the company is planning a semaglutide relaunch in November, suggesting near-term relief from product resumption. The Hindu provides more detail on operational revenue, which it says decreases year-on-year. Business Line outlets focus more directly on the financial impact of the semaglutide provision and the resulting net profit decline, emphasizing specific rupee amounts mentioned in their summaries.
Across coverage, the overall story is consistent: lower US sales and a semaglutide-related accounting provision weigh on quarterly profit, while base-market growth and a planned relaunch are positioned as potential offsets.
